Mustang Bio, Inc. (MBIO) stock
MBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.38−0.01 (-2.56%)
Close on Nov 18, 2026Market cap $2.88MP/E –Yield –
Mustang Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Mustang Bio's operating income for the twelve months ending Jun 30, 2026 was -$3.52M. For fiscal 2025 it was -$2.43M. The highest annual figure on record is -$2.43M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.43M | – |
| FY2024 | Dec 31, 2024 | -$16.25M | – |
| FY2023 | Dec 31, 2023 | -$49.26M | – |
| FY2022 | Dec 31, 2022 | -$76.16M | – |
| FY2021 | Dec 31, 2021 | -$66.72M | – |
| FY2020 | Dec 31, 2020 | -$56.81M | – |
| FY2019 | Dec 31, 2019 | -$45.89M | – |
| FY2018 | Dec 31, 2018 | -$31.22M | – |
| FY2017 | Dec 31, 2017 | -$31.79M | – |
| FY2016 | Dec 31, 2016 | -$11.36M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.17M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.06M | – |
| Q4 FY2025 | Dec 31, 2025 | -$670.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$624.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$885.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$253.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.02M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.46M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.54M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.23M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.74M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.31M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.89M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.32M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.43M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.85M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.24M | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.64M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.12M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.08M | – |
| Q2 FY2021 | Jun 30, 2021 | -$14.44M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.09M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.74M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.43M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.12M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.52M | – |
| Q4 FY2019 | Dec 31, 2019 | -$15.92M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.00M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.21M | – |
| Q1 FY2019 | Mar 31, 2019 | -$9.75M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.85M | – |
| Q3 FY2018 | Sep 30, 2018 | -$7.66M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.24M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.48M | – |
| Q4 FY2017 | Dec 31, 2017 | -$15.73M | – |
| Q3 FY2017 | Sep 30, 2017 | -$7.08M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.67M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.31M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.83M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.67M | – |
See a number that looks wrong?